文献速递免疫规划卫生政策与健康促进

美国2010年9月至2018年12月疫苗不良事件报告系统(VAERS)中65岁及以上成年人接种破伤风类毒素、减量白喉类毒素、无细胞百日咳疫苗(Tdap)的安全性回顾

Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.
PubMed 文献 · Vaccine · 2019-12-26

研究分析了2010年9月1日至2018年12月31日美国VAERS中65岁及以上人群接种Tdap后的1798份报告,其中104份(6%)为严重报告。最常见不良事件为注射部位红斑(26%)、疼痛(19%)、肿胀(18%)和红斑(18%),7例死亡均未归因于Tdap,数据挖掘未发现报告频率超预期的疫苗-不良事件组合。结论认为近十年Tdap推荐使用未发现新的安全性问题。

要点

  • 65岁及以上人群接种Tdap后严重报告占6%,最常见为注射部位反应。
  • 7例死亡均未归因于Tdap,数据挖掘未发现报告频率超预期的组合。
  • 近十年监测未发现新的安全性问题,与既往观察和上市前研究一致。

核心结论

  • 在近十年65岁及以上成年人推荐使用Tdap期间,未发现新的安全性问题;本次上市后回顾结果与既往上市后观察和上市前研究一致。

研究设计与样本

  • 对美国疫苗不良事件报告系统(VAERS)中2010年9月1日至2018年12月31日提交的65岁及以上人群接种Tdap后的报告进行检索和分析,共1798份报告。

主要发现

  • VAERS共收到1798份Tdap接种后报告,其中104份(6%)为严重报告。
  • 最常见不良事件为注射部位红斑(26%,n=468)、注射部位疼痛(19%,n=335)、注射部位肿胀(18%,n=329)和红斑(18%,n=321)。
  • 共识别7例死亡,均未归因于Tdap。
  • 严重非死亡报告中,最常见为神经系统疾病(35.1%,n=34)和感染及侵染类疾病(18.6%,n=18)。
  • 数据挖掘分析未发现任何疫苗-不良事件组合的报告频率高于预期。

关键数值与推荐

  • 严重报告定义为104份(6%),其余为非严重报告;严重报告审阅了可获得的医疗记录。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Advisory Committee on Immunization Practices (ACIP) recommends vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in persons ≥65 years of age. To date, few studies have assessed the safety of Tdap in this population. We aimed to summarize reports submitted to the Vaccine Adverse Event Reporting System (VAERS) following receipt of Tdap in this age group. METHODS: We searched for and analyzed U.S. VAERS reports of Tdap among individuals ≥65 years of age submitted from September 1, 2010 through December 31, 2018. We classified reports according to concurrent vaccination, seriousness, and outcome (death, non-death) and determined the frequency of reported adverse events (AEs). For serious reports, we reviewed available medical records. Data mining analyses were undertaken to detect disproportionality in reporting. RESULTS: VAERS received a total of 1,798 reports following Tdap, of which 104 (6%) were serious. The most common AEs were injection site erythema (26%; n = 468), injection site pain (19%; n = 335), injection site swelling (18%; n = 329), and erythema (18%; n = 321). We identified seven deaths; none were attributed to Tdap. Among serious non-death reports, nervous system disorders (35.1%; n = 34) and infections and infestations (n = 18.6%; n = 18) were most commonly reported. Data mining did not identify any vaccine-AE combination reported more frequently than expected. CONCLUSIONS: We did not identify any new safety concern over nearly a decade of recommended Tdap use among adults ≥65 years of age. Findings from this post-marketing review are consistent with prior post-marketing observations and pre-licensure studies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haber P, Moro PL, Ng C, et al. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018. Vaccine. 2019. PMID: 31883809. doi:10.1016/j.vaccine.2019.11.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。